Stockreport

Verastem: Downgrading To Buy Based On RAMP-203 Setback In Targeting KRAS G12C NSCLC [Seeking Alpha]

Verastem, Inc.  (VSTM) 
Last verastem, inc. earnings: 10/29 04:17 pm Check Earnings Report
US:NASDAQ Investor Relations: verastem.com
PDF VSTM pivots focus to VS-7375, an oral KRAS G12D "ON/OFF" inhibitor, with promising early efficacy and safety data in KRAS G12D NSCLC patients. Upcoming interim phase [Read more]